Mary-Ann El Sharouni

Mary-Ann El Sharouni

Auto-generated profile, based on publicly available information

Mary-Ann El Sharouni

Department of Dermatology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2021 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MSMary-Ann El Sharouni
Mary-Ann El Sharouni
TATasnia Ahmed
Tasnia Ahmed
AVAlexander H. R. Varey
Alexander H. R. Varey
SESjoerd G. Elias
Sjoerd G. Elias
AWArjen J. Witkamp
Arjen J. Witkamp
SLSerigne N. Lo
Serigne N. Lo
PURPOSE: Although the prognosis of patients with thin primary cutaneous melanomas (T1, ≤ 1.0 mm) is generally excellent, some develop recurrence. We sought to develop and validate a model predicting recurrences in patients with thin melanomas. METHODS: A Dutch population-based cohort (n = 25,930, development set) and a cohort from an Australian melanoma treatment center (n = 2,968, validation set) were analyzed (median follow-up 6.7 and 12.0 years, respectively). Multivariable Cox models were generated for local, regional, and distant recurrence-free survival (RFS). Discrimination was assessed using Harrell's C-statistic for each outcome. Each nomogram performance was evaluated using calibration plots defining low-risk and high-risk groups as the lowest and top 5% of the nomogram risk score, respectively. The nomograms' C-statistics were compared with those of a model including the current American Joint Committee on Cancer staging parameters (T-stage and sentinel node status). RESULTS: Local, regional, and distant recurrences were found in 209 (0.8%), 503 (1.9%), and 203 (0.8%) Dutch patients, respectively, and 23 (0.8%), 61 (2.1%), and 75 (2.5%) Australian patients, respectively. C-statistics of 0.79 (95% CI, 0.75 to 0.82) for local RFS, 0.77 (95% CI, 0.75 to 0.78) for regional RFS, and 0.80 (95% CI, 0.77 to 0.83) for distant RFS were obtained for the development model. External validation showed C-statistics of 0.80 (95% CI, 0.69 to 0.90), 0.76 (95% CI, 0.70 to 0.82), and 0.74 (95% CI, 0.69 to 0.80), respectively. Calibration plots showed a good match between predicted and observed rates. Using the nomogram, the C-statistic was increased by 9%-12% for the development cohort and by 11%-15% for the validation cohort, compared with a model including only T-stage and sentinel node status. CONCLUSION: Most patients with thin melanomas have an excellent prognosis, but some develop recurrence. The presented nomograms can accurately identify a subgroup at high risk. An online calculator is available at www.melanomarisk.org.au .

27 June 2019 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
MSMary‐Ann El Sharouni
Mary‐Ann El Sharouni
AWArjen J Witkamp
Arjen J Witkamp
VSVigfús Sigurdsson
Vigfús Sigurdsson
PDPaul J van Diest
Paul J van Diest
MLMarieke W J Louwman
Marieke W J Louwman
NKN.A. Kukutsch
N.A. Kukutsch

3 March 2021 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
MSM.A. El Sharouni
M.A. El Sharouni
AVA.H.R. Varey
A.H.R. Varey
AWA.J. Witkamp
A.J. Witkamp
TAT. Ahmed
T. Ahmed
VSV. Sigurdsson
V. Sigurdsson
CGC.H. van Gils
C.H. van Gils

23 October 2020 in JNCI Cancer Spectrum
Verified
Journal Article
Open access
PDF file
MSMary-Ann El Sharouni
Mary-Ann El Sharouni
PDPaul Johannes van Diest
Paul Johannes van Diest
AWArjen Joost Witkamp
Arjen Joost Witkamp
VSVigfús Sigurdsson
Vigfús Sigurdsson
CGCarla Henrica van Gils
Carla Henrica van Gils
Background: Our aim was to investigate the role of melanoma subtype on survival and focus on the effects stratified by Breslow thickness and ulceration status. Methods: Patients with cutaneous melanoma stage I, II, or III diagnosed between 2000 and 2014 were derived from the Dutch Nationwide Pathology Registry and overall survival data from the Netherlands Cancer Registry. Patients were followed until 2018. Using multivariable Cox proportional hazards models, hazard ratios were calculated for each melanoma subtype, per Breslow thickness category and ulceration status, and adjusted for age, sex, stage, and localization. Results: A total of 48 361 patients were included: 79.3% had superficial spreading melanoma (SSM), 14.6% nodular melanoma (NM), 5.2% lentigo maligna melanoma, and 0.9% acral lentiginous melanoma (ALM). In the total patient group, using SSM as the reference category, adjusted hazard ratios were 1.06 (95% confidence interval [CI] = 1.01 to 1.12) for NM, 1.02 (95% CI = 0.93 to 1.13) for lentigo maligna melanoma, and 1.26 (95% = CI 1.06 to 1.50) for ALM. Among patients with 1.0 mm or less Breslow thickness and no ulceration, NM showed a twofold increased risk (hazard ratio = 1.96, 95% CI = 1.58 to 2.45) compared with SSM. Compared with 1.0 mm or less SSM without ulceration, the hazard ratio for 1.0 mm or less SSM with ulceration was 1.94 (95% CI = 1.55 to 2.44), and the hazard ratio for 1.0 mm or less NM with ulceration was 3.46 (95% CI = 2.17 to 5.50). NM patients with tumors greater than 1.0 mm did not show worse survival than SSM patients with tumors greater than 1.0 mm. Conclusions: In this large nationwide study, ALM patients showed worse survival than SSM patients. Among patients with melanomas that were thin (1.0 mm or less), NM subtype patients also showed worse survival than SSM patients.

4 February 2019 in Annals of Surgical Oncology
Verified
Journal Article
Open access
PDF file
MSMary-Ann El Sharouni
Mary-Ann El Sharouni
AWArjen J. Witkamp
Arjen J. Witkamp
VSVigfús Sigurdsson
Vigfús Sigurdsson
PDPaul J van Diest
Paul J van Diest
Over recent years, sentinel lymph node biopsy (SLNB) recommendations in guidelines for cutaneous melanoma have changed considerably. We aimed to assess tre

1 September 2019 in JAMA Dermatology
Verified
Journal Article
Open access
PDF file
MSMary-Ann El Sharouni
Mary-Ann El Sharouni
AWArjen J. Witkamp
Arjen J. Witkamp
VSVigfús Sigurdsson
Vigfús Sigurdsson
PDPaul J. van Diest
Paul J. van Diest
Melanoma is one of the most rapidly increasing forms of cancer worldwide and is accountable for most skin cancer–related deaths.1-4 Familial atypical mole and melanoma syndrome leads to multiple primary melanomas, but primary melanoma can manifest multiple times outside the framework of familial syndromes. Follow-up guidelines and survival analyses usually consider only the initial melanoma and disregard the potential effects of multiple primary melanomas, which occur in 0.2% to 2.7% of patients with melanoma.5-16 Few epidemiologic data about tumor and patient characteristics of patients with multiple primary melanomas are available, necessitating better characterization of and prognostication for this group of patients.